| Acasti Pharma is a biopharmaceutical company that is focused on developing and commercializing products for rare and orphan diseases by using its drug delivery technologies. Co.'s primary drug candidate, GTX-104, is an IV formulation of nimodipine designed to treat subarachnoid hemorrhage, a rare brain disorder. Co.'s other drug candidates are: GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia, an orphan pediatric genetic neurodegenerative disorder in young children; and GTX-101, which is a topical bioadhesive film-forming bupivacaine spray for Postherpetic Neuralgia, which causes debilitating pain following infection by the shingles virus. We show 20 historical shares outstanding datapoints in our ACST shares outstanding history coverage, used to compute ACST market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACST market cap history over the course of time is important for investors
interested in comparing ACST's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACST versus a peer is one thing; comparing
ACST market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACST can fluctuate over the course of history.
With this page we aim to empower investors researching ACST by allowing them to research the ACST market cap history.